DGAP-News

STRATEC - Results for 1st Half of 2016 and new Financial Guidance

DGAP-News: STRATEC Biomedical AG / Key word(s): Half Year Results/Interim
Report
STRATEC - Results for 1st Half of 2016 and new Financial Guidance

21.07.2016 / 07:45
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

STRATEC - Results for 1st Half of 2016 and new Financial Guidance

- Two major company acquisitions successfully completed

- Substantial sales growth
- 6M/2016 at EUR 78.0 million (+11.5%; 6M/2015: EUR 70.0 million)
- Q2/2016 (organic) +2.6% to EUR 36.3 million (Q2/2015: EUR 35.5
million)

- Positive development in EBIT margin
- 6M/2016 at 16.2%* (-95 basis points; 6M/2015: 17.1%)
- Q2/2016 (organic) at 17.5% (Q2/2015: 17.3%)

- Financial forecast for the 2016 and 2017 financial years
- 2016 sales: EUR 175 million to EUR 182 million
- 2017 sales: EUR 205 million to EUR 220 million

- Earnings per share at EUR 0.87** in 6M/2016 (+4.8%; 6M/2015: EUR 0.83)

Birkenfeld, July 21, 2016

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX) today announced its financial results for the period from January
1, 2016 to June 30, 2016 with the publication of its interim report as of
June 30, 2016.


Key figures (EUR 01.01.- 01.01.- Change
000s) 06.30.2016 06.30.2015
Sales 78,032 70,012 +11.5%
EBIT* 12,616 11,986 +5.3%
EBIT margin (%)* 16.2 17.1 -95 bps
Consolidated net 10,312 9,807 +5.8%
income**
Earnings per share 0.87 0.83 +4.8%
(EUR) **


bps = basis points
* 2016 figure adjusted to exclude non-recurring items for transaction
activities
** 2016 figure additionally adjusted to exclude financing expenses and tax
expenses in connection with the acquisition of the Diatron Group and non-
recurring items arising from the external tax audit for the assessment
periods from 2009 to 2013.

STRATEC announced the acquisition of two companies - Diatron and Sony DADC
BioSciences (now STRATEC Consumables), - in March and June respectively of
the current financial year. These transactions have been successfully
completed and work has begun on integrating the new units into the STRATEC
Group's activities and structures.

At STRATEC, the first six months of 2016 were characterized by a strong
performance in the second quarter and the announcements of both
acquisitions. The following comments on the Group's results refer to the
figures adjusted to exclude the one-off items relating to the acquisitions.

Financial performance
Half-year sales at STRATEC AG grew by 11.5% to EUR 78.0 million. Diatron
contributed time-apportioned sales of EUR 10.5 million in the period from